It doesn't take a genius to see why PMCB is ready to run up as early as Monday morning!
Time is running out. You have to act fast if you want to profit.
My newest alert is a biotech gem that has just received a 20-year patent for its diabetes treatment and I believe that given the scale of news at the moment, the stock’s unbelievable low price is a major catalyst.
The diabetes treatment market is exploding at the moment. Globally diabetes is wreaking havoc and few companies are able to deliver the kind of treatment that is necessary and at the pace that it is needed.
The company you are about to look at understands this intimately. In the company’s own release it talked about the need for participation in doing its part in “bringing a treatment to tens of millions of these patients.”
PharmaCyte Biotech, Inc. (OTCQB: PMCB)
The diabetes problem is now a global problem and estimates put the cost of treating the disease at close to $1T. This has created a huge growth opportunity for companies that are working to bring much-need treatment to sufferers.
This reality is helping to spur on my newest play, PMCB.
PMCB has just a 20-year patent for "Melligen" cells that are a part of the company's therapy for Type 1 and insulin-dependent Type 2 diabetes.
The news has sent a flood of eyeballs to the company but I believe the full effect of the development is just about ready to take hold.
My reason for thinking this is simple: diabetes is now dominating the news. Recently there was a massive story in the Montana Standard about a . Patients are in crisis so the importance of PMCB’s novel cell-in-a-box technology is bound to take on greater significance.
Obviously I don’t want you to wait until the herd realizes how important PMCB is to the diabetes market. By then you might not be able to make a punt.
You certainly won’t be able to access PMCB’s upside for less than 10 cents… Yes, the play is super accessible right now and it has the right chart formation to match.
RSI levels are very close to support so there is massive upside and bounce potential at current levels.
Recent spikes in daily volatility suggest that the play might be getting ready to turn the corner and RUN.
Don’t let PMCB pick up pace without you. Start your research now.
Check out the chart…
Here’s a link to the chart:
bout PMCB
PMCB’s (PharmaCyte Biotech) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed.
Global Diabetes Drug Market Will Reach $55.3B Next Year
new report by visiongain predicts the world market for diabetes medications will reach . The antidiabetic medicines industry generated $35.6B in 2012, and its revenues will show strong growth to 2023. That sales forecast and others appear in Diabetes Treatments: World Drug Market 2013-2023, published in
pril 2013. Visiongain is a business information provider based in London, UK.
The analysis shows human insulins and analogues dominated the antidiabetics market in 2012. Furthermore, that submarket will maintain dominance in the overall diabetes treatments market to 2023.
lso, rapid uptake of dipeptidyl peptidase (DPP)-4 inhibitors will stimulate overall revenue growth, owing to their safety profiles and once-daily dosage regimens. The overall diabetes drugs market will thus achieve strong growth to 2013, especially from 2013 to 2017. Its future is promising, based on existing drugs and agents under development. It has strong, broad-ranging R&D.
Visiongain’s study concludes that an increase in the worldwide incidence of type 1 and type 2 diabetes, coupled with increases in obesity, will stimulate growth of the diabetes drugs market. In addition, the new study predicts the market will increase in competition, as the development of type 1 and type 2 diabetes treatments remains profitable for pharmaceutical companies in the short and long term.
lso, with companies entering the market from 2013, visiongain predicts more collaborations and alliances. In addition, the diabetes treatment industry and market will encourage combination therapy, with drugs developed as a monotherapy finding it harder in future to gain market share.
News Development
s Diabetes Becomes Global Epidemic, PharmaCyte Biotech's Insulin Producing Cells Receive 20 Years of Protection
NEW YORK, NY--(Marketwired - July 19, 2016) - Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of millions of these patients.
PharmaCyte recently learned from the U.S. Patent and Trademark Office (USTPO) that it now has 20 years of patent protection in the United States for the "Melligen" cells that are a part of the company's therapy for Type 1 and insulin-dependent Type 2 diabetes. The timing is perfect because the same research that laid out the dramatic rise in the numbers of people affected by diabetes, also found that the global cost of diabetes has ballooned to $825-billion per year.
Source:
To learn more about PMCB please visit their website:
Check out PMCB now.
Your Friend,
Jeff "The Mirkinator" Mirkin
IMPORTANT DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by Stellar Media Group, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “Stellar Media” refers to Stellar Media Group, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations.
lways do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only.
t most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Stellar Media’s business model is to receive financial compensation to promote public companies. We have been compensated $30K cash via bank wire by a third party, Ben, LLC, to conduct investor relations advertising and marketing for PMCB. This compensation is a major conflict of interest in our ability to be unbiased regarding . Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices.
ny non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Stellar Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. See full disclaimer at www.damngoodpennypicks.com/disclaimer.php.
This message was sent to xxxxxx@gmail.com from:
DamnGood PennyPicks | info@damngoodpennypicks.com | DamnGoodPennyPicks | 955 Massachusetts
ve,
| Cambridge, M
02139-3233
Email Marketing by
Manage Your Subscription
